CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • May 9th, 2018 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 23rd day of April, 2018 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Blaine H. McKee (the “Executive”).
DEVELOPMENT AND LICENSE AGREEMENTDevelopment and License Agreement • May 9th, 2018 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Development and License Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”) by and between Bayer HealthCare AG, a German corporation (“Bayer”), with its principal place of business at D-51369 Leverkusen, Germany, and ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, USA. Bayer and ImmunoGen are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties”.
CONFIDENTIAL TREATMENT REQUESTEDConfidential Treatment Requested • May 9th, 2018 • Immunogen Inc • Pharmaceutical preparations • Delaware
This Multi-Target Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and Eli Lilly and Company, an Indiana corporation (“Lilly”), with its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285. ImmunoGen and Lilly are sometimes each hereinafter referred to individually as a “Party” and collectively as the “Parties.”
